A new vaccine designed to fight Alzheimer’s disease could soon move to human testing, offering long-awaited hope to more than 7 million Americans currently living with the condition, according to researchers at the University of New Mexico Health Sciences.
In recent trials on mice and macaques, the experimental vaccine successfully targeted abnormal tau protein buildup in the brain. These tangled clumps of tau are considered a key driver of the cognitive decline associated with Alzheimer’s disease.
Lead researcher Kiran Bhaskar, a professor at the UNM School of Medicine, said the team is optimistic after seeing results in non-human primates. He explained that the vaccine appears ready for the next phase and the team is now seeking funding for human trials.
Targeting the root of memory loss
Unlike treatments that only manage symptoms, this vaccine aims to reduce the development of tau tangles—clusters of malformed proteins that interfere with brain function. These tangles form when tau undergoes a process called phosphorylation, which causes it to twist and accumulate between nerve cells.
The new vaccine triggers the immune system to produce antibodies that bind specifically to a portion of the faulty tau protein known as pT181. This binding process limits the spread of tangles and protects neurons from further damage.
Researchers first tested the vaccine on mice. After receiving the jab, the animals showed reduced tau buildup and improved memory performance in cognitive tests. Encouraged by those findings, the team then administered the vaccine to macaques, primates with brain structures closely resembling those of humans.
The primates also showed a strong immune response, which Bhaskar described as a critical step in moving toward human application.
Human applications on the horizon
In addition to testing the vaccine on animals, the research team also exposed blood samples from vaccinated monkeys to samples from human patients with mild cognitive impairment. The results showed that antibodies from the monkeys recognized and attached to the tau proteins in the human samples. This suggests that the treatment may work similarly in people.
The potential breakthrough comes at a crucial time. Experts estimate that nearly half of all Americans over the age of 55 are at risk of developing dementia. Current therapies often only slow the disease’s progression without addressing its biological roots.
If successful in humans, the vaccine could revolutionize dementia prevention and reduce the personal and economic toll of Alzheimer’s.
This promising development was first reported by GLOBE Magazine, which has closely followed the research and its implications for public health.
As the scientific team continues to seek backing for clinical trials, patients, families, and caregivers across the country remain hopeful that a real medical solution is finally within reach.
Jaja has a degree in journalism and took classes in international law and business communication. Her career spans roles at prominent international media outlets, including International Business Times, Celebeat and Delightful Philippines. As a news editor, Jaja covered a wide range of beats, including legal, business, economy, cryptocurrency, personal finance, gaming, technology, and entertainment.